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Abstract.  Human HT-1080 fibrosarcoma cells produce 
urokinase-type plasminogen activator (u-PA) and type 
1 plasminogen activator inhibitor (PAI-1). We found 
that after incubation of monolayer cultures with 
purified native human plasminogen in serum- 
containing medium, bound plasmin activity could be 
eluted from the cells with tranexamic acid, an ana- 
logue of lysine. The bound plasmin was the result of 
plasminogen activation on the cell surface; plasmin ac- 
tivity was not taken up onto cells after deliberate addi- 
tion of plasmin to the serum-containing medium. The 
cell surface plasmin formation was inhibited by an an- 
ticatalytic monoclonal antibody to u-PA,  indicating 
that this enzyme was responsible for the activation. 
Preincubation of the cells with diisopropyl 
fluorophosphate-inhibited u-PA led to a decrease in 
surface-bound plasmin, indicating that a large part, if 
not all, of the cell surface plasminogen activation was 
catalyzed by surface-bound u-PA.  In the absence of 
plasminogen, most of the cell surface u-PA was pres- 
ent in its single-chain proenzyme form, while addition 
of plasminogen led to formation of cell-bound two- 
chain u-PA.  The latter reaction was catalyzed by cell- 
bound plasmin. Cell-bound u-PA was accessible to in- 
hibition by endogenous PAI-1 and by added PAI-2, 
while the cell-bound plasmin was inaccessible to se- 
rum inhibitors, but accessible to added aprotinin and 
an anticatalytic monoclonal antibody. 
A model for cell surface plasminogen activation is 
proposed in which plasminogen binding to cells from 
serum medium is followed by plasminogen activation 
by trace amounts of bound active u-PA,  to form bound 
plasmin, which in turn serves to produce more active 
u-PA from bound pro-u-PA. This exponential process 
is subject to regulation by endogenous PAI-1 and 
limited to the pericellular space. 
H 
UMAN tumor cells are very commonly found to se- 
crete  plasminogen  activator  of the urokinase  type 
(u-PA) I (7). By this means they are able to recruit 
the proteolytic potential available in the high concentration 
of plasminogen  in plasma  and other body fluids.  Several 
lines of  evidence now strongly suggest that the invasive prop- 
erties of  tumor cells may be at least partly dependent on their 
proteolytic capability (2,  13, 22,  31, 45) mediated through 
the broad spectrum of  activity of  plasmin (20), and including 
its indirect actions in activating other latent proteases, such 
as collagenases (30, 47, 49). The expression of protease ac- 
tivity by tumor cells is proposed to facilitate their penetration 
of  basement membranes, capillary walls, and interstitial con- 
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hibitor; t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plas- 
minogen activator. 
nective tissues, allowing them to spread to other sites and es- 
tablish metastases (7). 
One aspect  of the tumor plasminogen activator/plasmin 
system has been problematic for some time: how is the pro- 
teolytic activity expressed in a plasma or interstitial tissue 
fluid environment dominated by very large excesses of an- 
tiplasmin  inhibitors?  The fibrinolytic  system, which  uses 
tissue-type plasminogen activator (t-PA), has been shown to 
escape these antiplasmins by focusing the participating t-PA 
and plasminogen on the fibrin substrate. Plasmin formed in 
situ is bound to fibrin through the lysine affinity sites located 
in the kringle structures of the plasmin heavy chain, and is 
thereby protected from plasmin inhibitors (5). The plasmin 
may be released and its enzyme activity assayed after treat- 
ment with agents which compete for the lysine affinity sites, 
such as 6-aminocaproic acid (19). Furthermore, the t-PA, by 
its interaction with fibrin, is protected from one of the spe- 
cific plasminogen activator inhibitors (PAIs), PAI-2 (19). 
Recent evidence has  shown that u-PA binds to specific 
receptor sites on many types of cells (3, 4, 43, 48),  so that 
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it may subsequently bind to the cell membrane and permit 
expression of enzyme activity at the site where it will have 
the maximum effect on the cell surface/cell matrix interface 
(34).  It is now appropriate to consider whether this location 
is functionally analogous to that for t-PA (i.e., fibrin), and 
to determine if receptor-bound u-PA may function to gener- 
ate  surface protease activity while surrounded by plasma 
protease inhibitors. Also, recent work (12, 23, 24, 33) has 
demonstrated the existence of cell surface plasminogen/plas- 
min binding sites,  and the resistance of bound plasmin to 
alpha-2-antiplasmin (33). It is therefore possible that recep- 
tor-bound u-PA may interact with a bound form of plasmino- 
gen to produce functionally active plasmin in spite of the 
presence of plasma inhibitors of both u-PA and plasmin. 
In this report we explore the ability of  human fibrosarcoma 
cells to produce plasmin on their surface while growing in 
serum-containing medium. We also investigated the effect of 
a range of plasmin and u-PA inhibitors, including anticata- 
lytic monoclonal antibodies. The results establish that func- 
tionally active plasmin can be generated on the surface of 
cells growing in serum-containing medium. Plasmin forma- 
tion is dependent on an interaction between bound active 
u-PA and bound plasminogen. We demonstrate that the avail- 
ability of bound active u-PA is itself dependent on the activa- 
tion of pro-u-PA by bound plasmin. 
Materials and Methods 
Cell Cultures 
Human fihrosarcoma cells (HT-1080 and CCL 121) were obtained from the 
American Type Culture Collection (Rockvitle, MD). Confluent cell layers 
were  grown in  plastic  Linbro  wells  (2  cm2;  Flow  Laboratories,  Inc., 
McLean, VA) in MEM supplemented with 10% heat-inactivated (56°C for 
60 min) FCS (Gibco Laboratories, Grand Island, NY), 100 IU/ml penicil- 
lin, and 50/zg/ml streptomycin. After reaching confluence, cells were rinsed 
three times with MEM containing 0.2% BSA, and then changed to either 
serum-free medium (0.5  ml) or medium containing 10%  heat-inactivated 
and plasminogen-depleted (i.e., absorbed with lysine-Sepharose; Pharma- 
cia Fine Chemicals, Uppsala, Sweden) FCS as indicated in the experiments. 
In the experiments on plasmin binding to cells from medium, human 
plasmin ("~18 caseinolytic U/mg; Kabi Diagnostica, Stockholm, Sweden) 
was added to the cultures at final  concentrations of 0-5/~g/ml. The cells 
were incubated for 3 h at 37°C before assay of cell-beund and supernatant 
plasmin (see below). For plasmin release experiments, cells were loaded for 
1 h at 37°C with 0-5 #g/ml plasmin in serum-free medium, and then rinsed 
three times with MEM. 
Human plasminogen (with glutamic acid NH2 terminal) was prepared 
by affinity chromatography on lysine-Sepharose (8) from freshly separated, 
unfrozen human plasma pretreated with l0/~M p-nitrophenyl guanidino- 
benzoate (NPGB),  1 mM PMSF, and 0.1 #g/ml of an anticatalytic murine 
monoclonal IgG antibody to human t-PA (ESP-2 in reference 21; American 
Diagnostica, Greenwich, CT). 
Inhibition studies made use of the following reagents added to cell cul- 
tures: an anticatalytic murine monoclonal IgG antibody to human plasmin 
(anti-pig 1 in reference 38; 20 #g/ml); aprotinin (Trasylol, Bayer,  Lever- 
kusen, FRG; 200 klU/ml); tranexarnic acid (Cyclokapron, Kabi Vitrum, 
Stockholm;  10 #M  and  100  tiM);  human PAI-2  minactivin (10),  PAI-2 
purified from cultures of human U-937  histiocytic lymphoma cells (19) 
(titration equivalent of 3.6 IU u-PA/ml); an anticatalytic murine monoclonal 
IgG antibody to human u-PA (clone 2 in reference 28;  10 #g/ml); the an- 
ticatalytic monoclonal antibody to human t-PA (10 #g/ml); a neutralizing 
murine monoclonal IgG antibody to human PAI-1 (27) (10 #g/ml); and di- 
isopropyl fluorophosphate (DFP)-inactivated u-PA (0-10 #g/ml). 
DFP-inactivated u-PA  for Competition Studies 
Active two-chain u-PA (Ukidan, Serono) was dissolved in 0.1 M Tris-HCl 
(pH 8.l), 0.1% Tween 80 (Tris/Tween). A freshly prepared solution of 500 
mM DFP (Sigma Chemical Co., St. Louis, MO) in isopropanol was added 
to yield a final DFP concentration of 5 raM. After thorough mixing, the 
sample was incubated for 2 h at 37°C, after which period addition of DFP 
was repeated as above. After renewed incubation for 2 h at 370C, the reac- 
tion was terminated by thorough dialysis at 0°C against Tris/Tween. No re- 
sidual DFP inhibitor could be detected when the preparation was tested in 
an activity assay of soluble uroldnase. 
Metabolic Labeling of CeU-bound u-PA 
Confluent layers of HT-1080 cells were rinsed three times with methionine- 
free MEM containing 0.2% BSA, and then prelabeled for 5 h at 37°C with 
170 #Ci/ml [3SS]methionine  (800 Ci/mmol; Amersham Corp., Arlington 
Heights, IL). Human plasminogen (50 #g/ml) and the neutralizing mono- 
clonal antibody to human PAI-1 (10 #g/ml) were added to one of two cul- 
tures, and the incubations continued for another 3 h. Aprotinin (200 ldU/ 
ml) was added to both cultures before the medium was removed, after which 
the cells were rinsed three times with Dulbecco's medium containing 0.2% 
BSA. The cell-bound u-PA was then eluted with 50 mM glycine-HCi (pH 
3.0) containing 0.1  M NaCl for 3 min at 23°C (44).  The acid eluate was 
neutralized with 0.5 M Tris-HCl (pH 7.8), before immunoprecipitation for 
2 h at 23°C with 3 #g/ml goat lgG antibodies to human u-PA (American 
Diagnostica) or 3  #g/ml goat IgG antibodies to human t-PA (American 
Diagnostica) as a control. Immune complexes were collected by adsorption 
to protein A-Sepharose in an end-over mixer for 1 h. Immunoprecipitates 
were washed several times with immunoprecipitation buffer of 10 mM Tris- 
HCI (pH 7.5), 50 mM NaCI, 0.5 % sodium deoxycholate, 0.5 % NP-40, 0.1% 
SDS containing 100 kIU/ml aprotinin, twice with PBS, and finally with 20 
mM Tris-HCt (pH 7.5).  Immunocomplexes were solubilized by boiling in 
Laemmli's (17) sample buffer under reducing conditions (10% beta-mercap- 
toethanol), and electrophoresed in 10%  SDS-polyacrylamide gels. Fixed 
gels were treated with Amplify  R (Amersham Corp.) and exposed to Kodak 
XAR-5 film at  -700C. 
u-PA Assays 
Cell culture supernatants were assayed for pro-u-PA and active u-PA by the 
following modification of an immunocapture method (41, 42).  Microtitre 
wells of polystyrene immunoplates (type 269620;  A/S  Nunc,  Roskilde, 
Denmark) were coated overnight at 37°C with 50 #1 of a solution of goat 
IgG antibodies to human u-PA (catalog No. 398; American Diagnostica). 
The coating solution contained 2.5 #g IgG/ml of 0.1 M sodium carbonate 
(pH 9.8). After rinsing, the wells were treated with conditioned medium (50 
#1) for 2 h at 23°C, then rinsed again. Half the wells were then treated with 
50 #1 of freshly prepared 2 #M NPGB (Sigma Chemical Co.) (6) for 20 
min at 37°C. The other half (controls) received 50 #l rinsing buffer (0.05 % 
Tween 20 in PBS). After rinsing, u-PA was assayed in all the wells by addi- 
tion of 40/zl of a solution containing plasminogan (100 #g/ml) and plasmin 
(10 ng/ml) in assay buffer (50 mM sodium glycinate [pH 7.8], 0.1% Triton 
X-100, 0.1% gelatin, and 10 mM 6-aminocaproic acid). The plates were in- 
cubated for 30 min at 37°C. This concentration of plasmin in the plasmino- 
gen incubation was sufficient to enable full realization of the potential activ- 
ity of pro-u-PA (32). The plasmin produced by this incubation was assayed 
by its thioesterase activity (11) by the addition of 200 ~1 of a solution con- 
taining 200 mM potassium phosphate (pH 7.5), 200 mM KCI, 0.1% Triton 
X-100, 220 #M Z-lysine thiobenzyl ester (Peninsula Laboratories, Inc., Bel- 
mont, CA), and 220 #M 5,5'-dithiobis(2-nitrobenzoic  acid) (Sigma Chemi- 
cal Co.). This mixture was incubated for 30 rain at 37°C, and the absorban- 
cies of the wells read at 405 nm. Active u-PA (60000 IU/mg) was purchased 
from Calbiochem-Behring  Corp. (La Jolla, CA) and pro-u-PA (potential ac- 
tivity 90,(300 IU/mg) was obtained from American Dingnostica. 
Pro-u-PA and active u-PA bound to the cell layer were recovered for im- 
munocapture assays by the same method as used in the metabolic labeling 
(above). Each culture well (2 cm  2) was eluted with 150/zl of acid glycine 
at pH 3 (44). For conditioned medium and cell-bound u-PA, the u-PA activ- 
ity assayed after NPGB treatment was expressed as a percentage of the total 
activity obtained without NPGB treatment, and this percentage was used as 
an index of pro-u-PA content (pro-u-PA index). The conditions used for the 
NPGB treatment were previously established (42) to allow selective inacti- 
vation of active u-PA, while leaving the pro-u-PA unchanged and still able 
to be activated by the added plasmin to the same extent as untreated pro- 
u-PA. 
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Figure 1.  Dependence of plasmin formation in serum medium on 
the concentration of added native human plasminogen. Confluent 
layers of HT-1080 cells were incubated for 3 h in MEM (0.5 ml) 
containing 10%  heat-inactivated and plasminogen-depleted FCS, 
with the addition of native human plasminogen to the concentra- 
tions shown. The conditioned media were harvested and the cells 
rinsed three times with PBS. Cells were treated with 1 mM tranex- 
amic acid in PBS to obtain the bound fraction of plasmin. Plasmin 
was assayed in the cell-bound fraction (o) and the medium (e) as 
thioesterase activity. 
Plasmin Assays 
The plasmin activity of culture supernatant samples (50 ttl) was assayed di- 
rectly by incubation with the thioester substrate solution above (200 pl) for 
30 rain (serum-free supernatants) or 3 h (serum-containing supernatants) at 
37°C. An estimate of the amount of active plasmin present was made from 
calibration curves using human plasmin dilutions in serum-free medium 
covering the appropriate  ranges of activity. 
Plasmin bound to the cell layer was recovered and assayed as follows. Af- 
ter harvest of culture medium, the cells were rinsed three times with PBS 
(plasmin assays of furuther rinses were negative), and then the bound plas- 
min was specifically eluted (24) with a solution of 1 mM tranexamic acid 
in the same rinsing solution 050 p.I/well),  Plasmin activity was assayed in 
eluate samples (50 pl) as above with an incubation time of 3  h  at 37°C. 
Tranexamic acid at 1 mM had no effect on the thioesterase activity of plas- 
min in these assays. 
Results 
Plasminogen Is Activated on the Cell Surface 
After addition of purifed preparations of human plasmino- 
gen to cultures of human fibrosarcoma cells (HT-1080) grow- 
ing in a medium with 10 % plasminogen-depleted FCS, plas- 
rain activity could be recovered as a bound fraction from the 
cell  layer.  Upon varying the concentration of added plas- 
minogen, the bound plasmin activity increased  in a  dose- 
dependent manner (Fig.  1). The binding was specific,  so that 
after  rinsing of the cells  with  isotonic buffer,  the plasmin 
could be released by 1 mM tranexamic acid. This agent dis- 
rupts  interactions  with  plasminogen or plasmin  which in- 
volve the  lysine-atiinity  sites  of the  heavy-chain  kringles 
(23). The plasmin released from HT-1080 cell surfaces was 
conveniently measured by its thioesterase activity,  a method 
which was  unaffected by the presence of tranexamic acid. 
Some plasmin activity was also detected in the medium. At 
a concentration of  40 #g/ml human plasminogen added to 0.5 
ml medium above a confluent 2-cm  2 cell layer, activity cor- 
responding to 28 ng plasmin could be recovered from the cell 
layer with tranexamic acid, while  10 ng was measurable in 
the medium after a 3-h incubation at 37°C.  This concentra- 
tion of plasminogen is well below the 200 #g/ml present in 
normal human plasma. 
To test whether the cell surface plasmin might have been 
derived from either preformed plasmin (added as a trace con- 
taminant with the plasminogen preparation) or from plasmin 
formed in the medium and subsequently bound to the cells, 
we added plasmin to the culture medium of HT-1080 cells. 
As shown in  Fig.  2,  virtually no plasmin activity was de- 
tected on the cell surface when the medium contained 10% 
FCS, while there was a considerable dose-dependent plasmin 
binding in the absence of serum.  These findings  indicated 
that the cell-bound plasmin activity found in the experiment 
shown in Fig.  1 was formed by activation of plasminogen on 
the surface of the cells. 
Incubation of cells carrying plasmin with fresh serum-free 
medium showed that ~40 % of the activity remained bound 
after 2 h at 37°C (Fig.  3, a  and b). When the cells were in- 
cubated in  10%  serum-containing medium, the same frac- 
tion (40%) of this activity could be recovered from the cells: 
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Figure 2.  Plasmin uptake onto 
HT-1080 cells from  serum-free 
and serum-containing media. Hu- 
man  plasmin (0-5  ttg/ml) was 
added to HT-1080 cell layers grow- 
ing  in  either  serum-free  MEM 
(SFM, 0.5 ml) (o) or MEM with 
10%  heat-inactivated FCS (SM) 
(e).  After  a  3-h  incubation at 
37°C the plasmin in  the bound 
fraction (a) and the conditioned 
media (b) were assayed as thio- 
esterase activity. Note the differ- 
ent scales used in Fig. 2 b for ac- 
tivity in SFM and SM. 
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Figure 3.  Plasmin  release  from HT-1080 
cells into serum-free and serum-containing 
media.  Confluent  layers of HT-1080 cells 
were first loaded with plasmin by incuba- 
tion for 1 h at 37°C in serum-free MEM (0.5 
ml) containing human plasmin (0-5 #g/ml). 
After  rinsing  the  cell  layers three  times, 
they were incubated for 2 h at 37°C with 
either  serum-free  medium  (o),  medium 
containing  10%  heat-inactivated and plas- 
minogen-depleted  FCS  (o),  or the  latter 
with tranexamic acid (100 #M) (B). Plas- 
min was then assayed in the cell-bound frac- 
tion (a) and the media (b). At the time of 
transfer to new media there was ,028 ng of 
plasmin  bound  to the cells  from the pre- 
treatment with 2.5 #g plasmin/well. 
the botmd plasmin was not inactivated by the serum. How- 
ever, only ,,o11% (compared to 60% for serum-free medium) 
could be detected in the serum-containing medium (Fig.  3 
b). When  1 mM tranexamic acid was added to the serum- 
containing medium, no plasmin activity could be recovered 
from the cells (Fig.  3 a). 
Cell Surface Plasrainogen Activation Is Catalyzed by 
Cell-bound u-PA 
HT-1080 cells are prolific producers of u-PA  (36)  but,  al- 
though they synthesize some t-PA, this does not appear to be 
secreted (Stephens,  R.,  unpublished observations).  To test 
which of the activators were responsible for the cell surface 
plasminogen activation, the cells were incubated with plas- 
minogen in the presence of monoclonal antibodies that in- 
hibit each of the activators. The results in Table I show that 
Table L Effects of  lnhibitors of Plasmin and u-PA on 
Formation of  Bound Plasmin on HT-1080 Cells in 
Serum Culture 
Bound plasmin  u-PA activity in 
activity  medium 
Incubation  3 h  17 h  3 h  17 h 
%  %  %  % 
Control  3.5  7. i  100.0  100.0 
Pig  100.0  100.0  l 11.0  83.0 
Pig  +  anti-u-PA  6.2  11.0  9.9  29.0 
Pig  +  anti-t-PA  101.0  123.0  102.0  81.0 
Pig  +  PAI-2  48.0  19.0  89.0  77.0 
Pig  +  aprotinin  13.2  7.8  93.0  99.0 
Pig  +  anti-Pig-1  2.8  6.4  90.0  88.0 
Pig  +  TA (10 #M)  9.7  34,0  116.0  87.0 
Pig  +  TA (100  #M)  2.2  13.0  92.0  95.0 
The following additions were made to cell layers growing in MEM (0.5 ml) 
containing 10 % heat-inactivated and plasminogen-depleted FCS: native human 
plasminogen (Pig,  40  t~g/rnl); anticatalytic  monoclonal antibody to  human 
u-PA (10 #g/ml); anticatalytic  monoclonal antibody to human t-PA (10 ttg/ml); 
PAI-2 (titration  equivalent of 3.6 IU u-PA/ml); anticatalytic  monoclonal anti- 
body to human plasmin (20 gg/ml); aprotinin (200  klU/ml); and tranexamic 
acid (TA). The cultures were incubated for the times shown before assay of 
cell-bound plasmin. The incubation with plasminogen was used as the 100% 
control for bound plasmin. 
inhibition of the enzymatic activity of u-PA resulted in virtu- 
ally no plasmin activity being detected on the cell surface, 
while inhibition of t-PA did not decrease the amount of plas- 
min activity, indicating that the cell surface plasminogen ac- 
tivation was catalyzed by u-PA. Bound plasmin activity was 
also reduced in cultures containing PAI-2 (10), aprotinin, or 
an anticatalytic monoclonal antibody to human plasmin (38). 
In HT-1080 cell cultures, u-PA is present both in the medi- 
um and bound to the cell surface (29).  To test whether the 
surface-bound u-PA was involved in the cell surface plas- 
minogen activation in serum cultures,  we preincubated the 
cells with either the anti-catalytic u-PA antibody or PAI-2, 
then washed the cells thoroughly before they were incubated 
with plasminogen in serum medium. Both inhibitors caused 
a  significant  decrease  in  the  cell-bound  plasmin  activity, 
while no inhibition of the u-PA activity in the medium was 
detected (Table II). 
An alternative method of studying the role of cell-bound 
vs.  free u-PA is illustrated  in Fig.  4.  u-PA is bound to its 
receptor at the surface of HT-1080 cells (29).  This binding 
does not involve the active site of u-PA (3), therefore, the 
u-PA receptor also binds u-PA that has been treated with the 
irreversible active-site titrant,  DFP  (29).  To decrease the 
Table II. Effect of  Pretreatment of  liT-10SO Cells with 
u-PA lnhibitors on Subsequent Ability  To Produce Bound 
Plasmin in Serum Culture 
Bound plasmin  u-PA activity 
Preincubation  Plasminogen  activity  in medium 
%  % 
Control  -  2.2  100.0 
Control  +  100.0  86.0 
Anti-u-PA  +  32.0  96.0 
PAI-2  +  54.0  86.0 
Confluent cell layers in serum medium (0.5 ml) were preincubated for I h at 
37°C with an anticatalytic  monoclonal antibody to human u-PA (10 p,g/ml) or 
PAI-2 (tritration  equivalent of 3.6 IU u-PA/ml). The cells were then rinsed 
three times with sernm-free MEM,  before incubation for 3 h at 37°C with 
MEM containing 10% heat-inactivated and plasminogen-depleted FCS and na- 
tive human plasminogen (40 t~glml).  The incubation with plasminogen was 
used as the 100% control for bound plasmin, while the control for u-PA was 
the incubation  without plasminogen. 
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Figure 4.  Effect of pretreat- 
ment  of HT-1080 cells  with 
DFP-u-PA on bound u-PA ac- 
tivity  and  ability  to produce 
bound plasmin  in serum me- 
dium.  Confluent  cell  layers 
of HT-1080 cells were prein- 
cubated for 18 h at 37°C with 
the  concentrations  shown  of 
DFP-u-PA  in serum-contain- 
ing  medium  (0.5 ml).  After 
rinsing three  times,  the cells 
were incubated for 1 h at 37°C 
with  MEM  containing  10% 
heat-inactivated and plasmin- 
ogen-depleted FCS,  with  ad- 
dition  of native human  plas- 
minogen (40 #g/ml). After incubation, half the replicate wells were 
rinsed and treated with acid-glycine to recover the total bound u-PA 
(o) which now included DFP-u-PA,  pro-u-PA, and active u-PA. 
The other wells were used to recover bound plasmin (e) by elution 
with tranexamic acid. 
amount of receptor-bound, catalytically active u-PA, we pre- 
incubated the HT-1080 cells for 18 h  with DFP-inactivated 
u-PA which, when present in a large molar excess, resulted 
in a decrease of ,-70%  in surface-bound u-PA that was re- 
leased by acid treatment (44).  Concomitantly, there was a 
comparable decrease in the amount of plasmin generated on 
the cell surface (Fig. 4).  These results indicate that a  large 
part, if not all, of the cell surface plasminogen activation in 
serum cultures was catalyzed by the surface-bound u-PA. 
Surface-bound Plasmin Activates Pro-u-PA 
u-PA is released into the medium of HT-1080 cells as a single- 
chain proenzyme, pro-u-PA, that can be converted to a two- 
chain active u-PA by plasmin (26,  38). The enzymatic activ- 
ity of the proenzyme is at least 250-fold lower than that of 
the two-chain u-PA (32), and it does not react with PAI-1 (1) 
or PAI-2 (40,  50). With the use of metabolic labeling, recov- 
ery of receptor-bound u-PA by acid treatment, immunopre- 
cipitation, SDS-PAGE under reducing conditions, and fluo- 
rography,  we found  (Fig.  5)  that the  receptor-bound u-PA 
was almost exclusively present in the single-chain form when 
the  cells were incubated  in  serum medium without added 
plasminogen.  By contrast,  virtually all the receptor-bound 
u-PA was in the two-chain form when the cells were incu- 
bated with 50 #g/ml human plasminogen in serum medium 
for 3 h. 
As an alternative way of distinguishing between pro-u-PA 
and active u-PA, we took advantage of the fact that low mo- 
lecular weight active-site reagents for u-PA do not bind to 
pro-u-PA (26). One of these, NPGB, was used to distinguish 
between the two u-PA forms in an immunocapture assay (41, 
42). The u-PA present in samples was first absorbed by u-PA 
antibodies bound to microtitre wells. Half the wells for each 
sample were treated with NPGB, the other half were control 
treated. The total u-PA activity (pro-u-PA plus active u-PA) 
in the untreated wells and the pro-u-PA in the treated wells 
were then measured by a coupled plasminogen activator as- 
say in the presence of an initial concentration of 10 ng/ml 
plasmin, and the results expressed as a pro-u-PA index (see 
Figure 5. Activation of cell-bound u-PA proenzyme in serum me- 
dium after addition of plasminogen.  Confluent layers of HT-1080 
cells were prelabeled for 5 h at 37°C with [35S]methionine. After 
restoring  complete  medium  with  10%  heat-inactivated and plas- 
minogen-depleted FCS, native human plasminogen (50 #g/ml) was 
added and the incubation continued another  3 h.  Aprotinin (200 
kIU/ml) was added before harvest of medium, and the rinsed ceils 
were treated with acid-glycine to recover the bound u-PA fraction. 
Acid eluates were neutralized and immunoprecipitated  with goat 
antibodies to u-PA, before SDS-PAGE under reducing conditions. 
The fluorogram shows (lane 1) control immunoprecipitate of cul- 
ture without plasminogen with goat antibodies to human t-PA; (lane 
2) culture without plasminogen immunoprecipitated with goat anti- 
u-PA antibodies; and (lane 3) culture with plasminogen immuno- 
precipitated with u-PA antibodies. 
Materials and Methods). Fig. 6 a  shows that the proportion 
of the total surface-bound u-PA that was present as pro-u-PA 
decreased dramatically when the cells were incubated with 
human plasminogen in serum medium, compared with plas- 
minogen-free cultures (from "90%  to "10%).  These find- 
ings suggest that conversion of the surface-bound pro-u-PA 
to active u-PA by plasmin plays a role in cell surface plas- 
minogen activation. 
In the experiment described in Fig. 6, there was a mark- 
edly lower amount of total u-PA activity on the cells incu- 
bated with plasminogen (Fig. 6 b). We found that this differ- 
ence was nearly abolished when a monoclonal antibody that 
neutralizes human PAL1  was added during  the incubation 
(Fig. 6 b). HT-1080 cells release large amounts of PAL1 (27) 
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Figure 6.  Activation of cell-bound  u-PA proen- 
zyme in sertma  medium after addition of plasmino- 
gen. Confluent layers of HT-1080 cells were incu- 
bated with MEM containing 10% heat-inactivated 
and plasminogen-depleted FCS and native human 
plasminogen (40/~g/ml).  After the time intervals 
shown, aprotinin (200 klU/ml) was added and the 
rinsed cells were treated with acid-glycine to re- 
cover the bound fraction of u-PA. The u-PA in the 
neutralized eluate was assayed by an immunocap- 
ture method, using an NPGB inactivation step to 
determine the pro-u-PA index (see Materials and 
Methods). a shows the pro-u-PA index for cultures 
without (o) and with (e) plasminogen. The zero- 
time sample with plasminogen shows some change 
already  occurred  during  work-up of the cells,  b 
shows the eluted u-PA activity from cultures with- 
out plasminogen (o), with plasminogen (e), and 
with plasminogen and a neutralizing monoclonal 
antibody to human PAI-1 (10 #g/ml)  (.). 
that binds to active u-PA, but not to pro-u-PA (1). The appar- 
ent decrease in total u-PA after incubation with added plas- 
minogen (Fig.  6  b)  can,  therefore,  be attributed  to  PAI-I 
binding to active u-PA on the cell surface and inhibiting its 
activity in the subsequent assay. 
To prevent the interference of PAI-1, we included the neu- 
tralizing PAI-1 antibody in the next experiment in which we 
studied the effect of the plasmin inhibitor aprotinin and of an 
anticatalytic monoclonal antibody to human plasmin on the 
conversion of pro-u-PA to active u-PA. As shown in Table 
III, both these inhibitors  increased the relative amount of 
pro-u-PA,  thus  demonstrating  that  the  activation of cell- 
bound pro-u-PA was catalyzed by plasmin. To study whether 
this was an effect of cell-bound plasmin, we also tested the 
effect of tranexamic acid in a concentration of 100 #M, which 
completely inhibits binding of plasmin to the cells, but does 
not affect the ability of plasmin to activate pro-u-PA in solu- 
tion  (Stephens,  R.,  unpublished  results).  This  treatment 
markedly decreased the relative amount of active u-PA, indi- 
cating that the activation of the cell surface pro-u-PA is cata- 
lyzed by the surface-bound plasmin. 
Table IlL Effectors of  Pro-u-PA Activation and Plasmin on 
the Surface of  HT-1080 Cells in Serum Medium 
Pro-u-PA  Bound plasmin 
Incubation  index  activity 
%  ng 
Control  85  0.0 
Pig  50  12.0 
Pig  +  anti-PAI-1  21  33.0 
Pig  +  anti-PAI-1  +  aprotinin  93  3.0 
Pig  +  anti-PAI-1  +  anti-Pig-1  72  2.1 
Pig +  anti-PAI-1  +  TA (100/~M)  88  0.0 
Confluent cell layers were incubated for 2 h at 37°C with MEM (0.5 ml) con- 
raining 10 % heat-inactivated and plasminogen-depleted FCS with the following 
additions: native human plasminogen (Plg, 40 #g/ml); neutralizing monoclonal 
antibody  to human PAI-I  (I0/~g/ml); aprotinin  (200  klU/ml);  anticatalytic 
monoclonal antibody to human plasmin (20/xg/ml); and tranexamic acid (TA). 
Half the wells were then treated with aprotinin (200 klU/ml) and used for assay 
of bound u-PA and its pro-u-PA index (see Materials and Methods). The other 
half were used for elution and assay of bound plasmin. 
Discussion 
The findings from these experiments provide functional evi- 
dence for the u-PA-catalyzed activation of plasminogen on 
the surface of human fibrosarcoma cells growing in serum- 
containing medium. The new findings include the require- 
ment for binding of plasminogen, the ability of bound u-PA 
to activate plasminogen,  the presence of pro-u-PA on the 
cells, the ability of bound plasmin to activate pro-u-PA, and 
the ability of endogenous PAI-1, as well as added PAI-2, to 
regulate the surface plasminogen activation. By these means 
tumor cells can acquire the broad-spectrum proteolytic ac- 
tivity of plasmin, bound to their surface in such a way that 
they are protected from inactivation by serum protease inhib- 
itors and ideally situated to be used in the degradation of the 
pericellular matrix. 
In this report the bound u-PA was shown to be the fraction 
most active in forming bound plasmin; however, it was not 
rigorously established if this u-PA was present on the previ- 
ously identified and characterized specific receptors (3, 29), 
although this is very likely since (a) HT-1080 cells are known 
to possess specific u-PA receptors on their membranes (29); 
(b) the same acid elution method was used to recover bound 
u-PA as has been used in the receptor studies (44); and (c) 
a large proportion of the bound u-PA could be competed out 
by DFP-inactivated u-PA, which can bind to the u-PA recep- 
tor (29) but not to other known u-PA binding proteins which 
require the active site, such as PAI-1 and PAI-2 (1, 40, 50). 
Before addition of native plasminogen to the serum cul- 
tures, it was clear that the vast majority of u-PA secreted by 
the fibrosarcoma cells, and present on the cell surface, was 
in the single-chain, proenzyme form. This is consistent with 
several previous reports, including  our recent survey (42), 
indicating that many adherent cells secrete u-PA as its proen- 
zyme. The proenzyme form has been characterized exten- 
sively by several groups, and recently finally established as 
being a true proenzyme, with little or no intrinsic activity (9, 
32). After addition of native plasminogen, bound u-PA was 
found to be in the two-chain form, a  reaction known to be 
catalyzed by plasmin (26, 38). However, under serum culture 
conditions, in the presence of a large excess ofplasmin inhib- 
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Figure 7. Model for cell surface plasminogen activation. In this pro- 
posed model, u-PA receptors (u-PA-R) and plasminogen receptors 
(pig-R) are depicted on the cell membrane. Before exposure to plas- 
minogen (pig) virtually all the bound u-PA is present as pro-u-PA 
(open squares), but it is assumed that some active u-PA molecules 
exist (solid squares).  On plasminogen (open rectangles)  binding 
(which may be precluded by the presence of tranexamic acid), plas- 
min (pl, solid rectangles)  is formed on the cell by the action of the 
bound active urokinase. This step may be inhibited by PAI-1 and 
PAI-2, and by an anticatalytic monoclonal antibody to u-PA (anti- 
u-PA-ab).  The bound plasmin thus formed is resistant to inhibition 
by the alpha-2-antiplasmin present in the serum medium, but sensi- 
tive to inhibition by aprotinin and an anticatalytic monoclonal anti- 
body to plasmin (anti-pl-ab). As active plasmin becomes available, 
it catalyzes the activation of more bound pro-u-PA to active u-PA, 
thus amplifying the proteolytic system. Activation of pro-u-PA is 
inhibited by tranexamic acid (which prevents plasminogen bind- 
ing), aprotinin, and anticatalytic monoclonal antibody to plasmin. 
itors, the binding of plasminogen and its activation product 
(plasmin) to the cell surface was a necessary prerequisite for 
formation of the two-chain u-PA. It appears likely that the 
activation of pro-u-PA occurs when it is  actually surface 
bound. However this was not rigorously established by the 
present findings.  It is conceivable that cell-bound plasmin 
activates pro-u-PA in the immediate environment of the cells 
and that the u-PA formed could subsequently exchange with 
bound pro-u-PA. 
The binding  and  subsequent protection of plasmin  was 
abolished by low concentrations of the lysine analogue, tran- 
examic acid, as reported by others (23). It is therefore likely 
that plasmin binding involves the lysine affinity sites situated 
in  the  heavy-chain kringles  of plasmin.  Plasmin  released 
from the cells was partially inactivated in the serum medium. 
As long as the plasmin remained bound,  it was  protected 
from serum inhibitors (33) but could be inhibited by aproti- 
nin or an anticatalytic monoclonal antibody. 
This result provides a possible explanation for the effec- 
tiveness of aprotinin in certain therapeutic applications, such 
as the promotion of healing of corneal ulcers (37).  Plasmin 
has been shown to be produced in this condition, yet one 
would expect that it would be inactivated by serum inhibitors. 
If a significant fraction is bound to cells, however, this may 
escape inhibition and retard development of healing tissue 
until an effective inhibitor is applied externally. The plasmin 
found on HT-1080 cells after addition of native plasminogen 
to serum cultures was demonstrated to be the product of  plas- 
minogen activation by bound u-PA. It was not taken up from 
serum medium; in fact, the experiments with plasmin uptake 
and release in serum medium clearly established the exis- 
tence of a one-way movement of plasmin activity from the 
cells into the medium, and not vice versa. In keeping with 
this  result,  more plasmin  was  measurable  in the  fraction 
bound to cells than in the serum medium after addition of 
plasminogen. It is very likely that the plasmin activity, which 
could be measured in the serum medium, represented the 
thioesterase activity of plasmin complexes with serum inhib- 
itors rather than free plasmin. These complexes retain activ- 
ity towards small substrates, but their proteolytic activity is 
sterically hindered (46). Plasmin formation was not detected 
when cells were grown in serum medium without addition 
of a native preparation of plasminogen (Stephens, R., unpub- 
lished observation); the bovine plasminogen present in the 
FCS supplied commercially for cell cultures appeared to be 
denatured. A purified native preparation of  bovine plasmino- 
gen was able to form cell surface plasmin activity; there was 
no apparent species specificity. 
The model which we propose for plasminogen activation 
on cells growing in serum medium can be summarized in the 
following steps (Fig. 7). Plasminogen must first bind to the 
cell surface via its heavy-chain kringles. Formation of cell- 
bound plasmin from bound plasminogen is initiated by the 
action of trace amounts of active bound u-PA. This leads to 
rapid activation of u-PA proenzyme, which in turn enables 
more activation of bound plasminogen, formation of more 
plasmin,  and  so on.  The availability of trace amounts of 
bound active u-PA to initiate plasminogen activation is clear- 
ly a critical requirement, but in the HT-1080 system we have 
been unable to demonstrate a plasmin-independent mecha- 
nism for proenzyme activation (e.g., by pulse-chase experi- 
ments). On the contrary, we have found that cultures of sev- 
eral  human  leukemia cell  lines  produce active urokinase 
without requiring added plasminogen (42).  It is therefore 
possible  that  other  nonplasmin  serine  proteases  do  exist 
which could be important in the initiation of  plasminogen ac- 
tivation on the cell surface. 
Once initiated, this exponential process was found to be 
susceptible to regulation by endogenous PAI-1 produced by 
the HT-1080 cells.  Its control of bound u-PA was demon- 
strated by the use of a neutralizing antibody to PAI-1, which 
caused the formation of more active, bound u-PA and more 
plasmin than seen on control cells. Preparations of purified 
PAI-1 were not used in these experiments since this would 
have required pretreatment with denaturants (15), which could 
have adversely affected the cells. The observed production 
of cell surface plasmin, therefore, represents the net result 
of the pro-u-PA activation reaction, the activation of plas- 
minogen, the partial inhibition of active u-PA by PAI-1, as 
well as the dissociation of plasmin from its binding sites. 
PAI-1 can exist in both active and latent forms (15),  and 
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voir of the active form (18,  34).  Thus a high concentration 
of bound PAI-1 exists  in the immediate vicinity of the cell 
surface plasminogen activation system,  while free PAI-1 in 
the liquid phase is known to more rapidly lose its capacity 
to inhibit activators after secretion (25). The cell surface ac- 
tivation of plasminogen was also inhibited by addition of ex- 
ogenous PAI-2. This could have significance because PAI-2 
is secreted by activated macrophages (10, 39); therefore, in- 
tratumoral macrophages could have a role in reducing the in- 
vasive proteolytic capacity of tumor cells. 
The binding of the proenzyme and enzyme components of 
plasminogen activation to the cell surface, the accumulation 
of a regulatory inhibitor (PAl-l) in the cell substratum, and 
the  abundance  of plasmin  inhibitors  in  the  serum  liquid 
phase, all serve to limit plasminogen activation and the ac- 
tion of plasmin to the immediate proximity of the cell sur- 
face, just as  t-PA  and plasmin are  limited to fibrin in the 
course of fibrinolysis (5).  Furthermore, in recent immuno- 
fluorescence and ultrastructural  studies, u-PA was localized 
to the focal contact sites of human fibroblasts and HT-1080 
fibrosarcoma cells, as well as to areas of cell to cell contacts 
and to cell extensions (34,  35).  Extracellular u-PA antigen 
had a  striking  colocalization with the cytoskeletal  protein 
vinculin at focal contacts (14, 35). Depletion of PAI-1 antigen 
in stria-like  areas from an otherwise uniform deposit was 
also observed (34).  Based on these distribution patterns, it 
is likely that cells express u-PA-mediated focal proteolysis. 
Limited  plasmin  activity  may  then  serve  to  facilitate  the 
detachment of cells from contacts with the substratum that 
are maintained by the cell adhesion molecules, such as inte- 
grins (16). Overexpression of the proteolytic activity of plas- 
min in the case of tumor cells may be the enabling condition 
for these sites to become the invasion front that penetrates 
adjoining normal tissue. 
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